Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Avid Bioservices, Inc. | peregrine_8k-ex9901.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2012
PEREGRINE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
0-17085
|
95-3698422
|
|
(State of other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
14282 Franklin Avenue, Tustin, California 92780
|
||
|
(Address of Principal Executive Offices)
|
||
|
Registrant’s telephone number, including area code: (714) 508-6000
|
||
|
Not Applicable
|
||
|
(Former name or former address, if changed since last report)
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
o
|
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On May 21, 2012, Peregrine Pharmaceuticals, Inc. issued a press release announcing top-line clinical trial results from a randomized, double-blind, placebo-controlled Phase II trial evaluating two dose levels of bavituximab plus docetaxel versus docetaxel plus placebo (control arm) in second-line non-small cell lung cancer patients.
A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:
|
Exhibit
Number
|
||
| 99.1 | Press Release issued May 21, 2012. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PEREGRINE PHARMACEUTICALS, INC. | |||
|
Date: May 21, 2012
|
By:
|
/s/ Paul J. Lytle | |
| Paul J. Lytle | |||
| Chief Financial Officer | |||
3
EXHIBIT INDEX
|
Exhibit
Number
|
Description | |
|
99.1
|
Press Release issued May 21, 2012.
|
4